INPOZA 50

  • Product Description:

Inpoza 50 mg Tablet (Olaparib) is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer both as monotherapy or following platinum-based chemotherapy. Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasis and cell death.

  • Product Features:

Product Name INPOZA 50
Generic Name Olaparib INN 50 mg
FDA Approved Indications
    Ovarian cancer-

  • for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary
    peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
  • for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated
    (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Select patients for
    therapy based on an FDA-approved companion diagnostic for Inpoza.
    Breast cancer-

  • in patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment. Select patients for therapy based on an FDA-approved companion diagnostic for Inpoza.
Packaging Each commercial box contains 8 x 8’s tablets in Alu-Alu blister. Total 64 tablets in a box.
Prescribing Information INPOZA 50 (PDF)